You are here

Article Text

Article menu
Download PDFPDF
Original research
Health conditions and the risk of home injury in French adults: results from a prospective study of the MAVIE cohort
  1. Madelyn Yiseth Rojas Castro1,2,
  2. Marta Avalos1,3,
  3. Benjamin Contrand1,2,
  4. Marion Dupuy4,
  5. Catherine Sztal-Kutas4,
  6. Ludivine Orriols1,2,
  7. Emmanuel Lagarde1,2
  1. 1U1219, INSERM, Bordeaux, Nouvelle-Aquitaine, France
  2. 2U1219, Universite de Bordeaux, Bordeaux, Aquitaine, France
  3. 3SISTM Team, Inria, Talence, Aquitaine, France
  4. 4Calyxis, Centre of Risk Expertise, Niort, France
  1. Correspondence to Emmanuel Lagarde, Bordeaux, Aquitaine, France; emmanuel.lagarde{at}u-bordeaux.fr

Abstract

Background Home injury (HI) is a significant cause of mortality and morbidity in adults of all ages. Health conditions significantly impact HI among old adults, but little is known for other adults.

Study design Prospective cohort study.

Objective We assessed the associations between health-related factors and HI’s risk in a French study, the MAVIE (Mutualistes pour la recherche contre les Accidents de la VIE courante) cohort.

Methods Poisson mixed models were fitted using health-related data information (diseases, treatments and disabilities) at baseline and the number of injuries prospectively recorded during the follow-up, adjusting for significant sociodemographics and exposure to a range of home activities. Attributable fractions were estimated based on risk ratio (RR) estimations measured in the fully adjusted models.

Results A total of 6146 dwelling adults aged 15 or older were followed up for 5.1 years on average. Vertigo or dizziness (RR=2.36, 95% CI 1.06 to 5.01) and sciatica or back pain (RR=1.49, 95% CI 1.08 to 2.05) were independently associated with an increased risk of HI. These two groups of conditions showed the most significant associations among people aged 15–49, whereas musculoskeletal diseases other than rachialgias and arthropathies were the most significant health-related risk factor in people aged 50 and older. Sciatica or back pain represented the highest burden of HIs in overall adults (8%) and among people aged 15–49 (12%).

Conclusion Our results suggest that adults with musculoskeletal disorders and vertigo or dizziness symptoms have a higher risk of HI, regardless of age.

  • home
  • community
  • mixed methods
  • longitudinal
  • cohort study
  • web-based

Data availability statement

Data are available on reasonable request. Personal health data underlying the study are protected by the French Data Protection Act and cannot be shared publicly. The large number of variables allows data to be indirectly identifiable and making such data freely available is prohibited. Furthermore, an authorization from the CNIL, the French Data Protection Authority, may be required to transfer the data, especially abroad. The MAVIE observatory protocol was approved by the CNIL on May 28, 2013 (decision DR-2013-288). Data from this study can be obtained upon request from the steering committee (http://www.observatoire-mavie.com/contacter-equipe-MAVIE.aspx), as well as from the corresponding author (emmanuel.lagarde@u-bordeaux.fr).

https://doi.org/10.1136/injuryprev-2020-044033

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available on reasonable request. Personal health data underlying the study are protected by the French Data Protection Act and cannot be shared publicly. The large number of variables allows data to be indirectly identifiable and making such data freely available is prohibited. Furthermore, an authorization from the CNIL, the French Data Protection Authority, may be required to transfer the data, especially abroad. The MAVIE observatory protocol was approved by the CNIL on May 28, 2013 (decision DR-2013-288). Data from this study can be obtained upon request from the steering committee (http://www.observatoire-mavie.com/contacter-equipe-MAVIE.aspx), as well as from the corresponding author (emmanuel.lagarde@u-bordeaux.fr).

    View Full Text

    Footnotes

    • Contributors All authors contributed to the study conception and design. Methodology: MYRC, MA and EL. Formal analysis: MYRC. Investigation: MYRC, MA, LO and EL. Writing original draft: MYRC. Writing review and editing: MA, BC, MD, CS-K, LO and EL. Supervision: EL and MA. Project administration: EL, CS-K and MD. Funding acquisition: EL, CS-K and MD.

    • Funding This study was financed jointly by the Institut de recherche en santé publique (IReSP) (CONV 067-00187II), the Agence nationale de sécurité du medicament et des produits de santé (conv 2014S029), the Université de Bordeaux and the Région Nouvelle Aquitaine as part of the Cassiopée project (conv 2014-1R30504 -00003101). MYRC is the recipient of an INSERM/Région Nouvelle Aquitaine doctoral grant (2017-1R40301 Thèse 00013329) and is affiliated to the Graduate Digital Public Health Program supported within the framework of the PIA3 (Investment for the future) (17-EURE-0019). The MAVIE observatory has the support of the mutual insurance companies: Fondation MAIF, MAAF, MACIF and Decathlon (AD 13339, AD 15404).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.